Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
NCT06213857

Beneficial Effect of Silymarin in Ulcerative Colitis

Led by Tanta University · Updated on 2025-03-05

44

Participants Needed

2

Research Sites

17 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to evaluate the possible beneficial effect of silymarin in Ulcerative Colitis adult patients receiving mesalamine. This is trial that will be conducted on 44 adult patients with Ulcerative Colitis. Patients will be enrolled after obtaining an informed consent from them or their guardians. Patients will be recruited from Rajhy Hospital Outpatient Clinics and Health Insurance Outpatient Clinics at Mabarra Hospital in Assiut, Egypt. The patients will be randomized based on hospital admission days into two groups: * Group Ⅰ (Control group): 22 patients will receive Mesalamine (2g/day) + Azathioprine (50mg/day) for 3 months. * Group Ⅱ (Silymarin group): 22 patients will receive Mesalamine (2g/day) + Azathioprine (50mg/day) + Silymarin (140 mg/day) for 3 months. The primary outcome will be clinical improvement defined as a 2 point or more decrease in the Mayo score from baseline. The secondary outcomes will be the change in the level of fecal calprotectin, superoxide dismutase and TNF-α.

CONDITIONS

Official Title

Beneficial Effect of Silymarin in Ulcerative Colitis

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults of both sexes aged from 18 years to 65 years
  • Adults with normal kidney and liver functions
  • Patients who sign the consent and willing to participate in the study
  • Patients with UC according to American College of Gastroenterology Clinical Guidelines for diagnosis Ulcerative Colitis having clinical signs and symptoms with a completed medical workup, colonoscopy, pathological and laboratory data confirming UC
Not Eligible

You will not qualify if you...

  • Previous hypersensitivity or anaphylactic reaction to silymarin
  • Significant renal and hepatic impairment
  • Patients who refuse to participate
  • Pregnant women, breastfeeding women and smokers
  • Patients taking corticosteroids or biological therapy
  • Patients taking any other antioxidants
  • Patients having other concomitant diseases where oxidative stress is involved in the etiology such as chronic liver disease, pulmonary infection

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Mabarra Hospital

Asyut, Egypt, 71511

Actively Recruiting

2

Rajhy Hospital

Asyut, Egypt, 71511

Actively Recruiting

Loading map...

Research Team

A

Ahmad A Ahmad Eltayeb, Cl.Ph

CONTACT

D

Dalia R Mohammed ElAfify, Asst.Prof

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here